Erlotinib Adverse Event Report 2018


This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • uniqueid report_date
  • patient_summary
  • patient_gender
  • patient_age
  • drug_products
  • drug_reactions


Esbriet (pirfenidone) is used to treat a lung disease called idiopathic pulmonary fibrosis (IPF). IPF causes scar tissue to form deep within your lungs. The scar tissue thickens and becomes stiff or thick over time, which can make it harder for your lungs to work. Decreased lung function can make it hard for you to breathe. Other medical problems can occur when your brain, heart, and other organs do not get enough oxygen. The cause of IPF is often unknown, but this condition is a progressive disease that can be fatal. Esbriet is not a cure for IPF, but this medicine may slow the progress of this disease.